Cryoport, Inc.
No enriched coverage for $CYRX in the last 7 days.
No SEC Form 4 filings for $CYRX in the last 30 days.
See all $CYRX insider activity →BTIG maintained a Buy rating on CryoPort with a $25 price target, suggesting a 49% upside from its Sep 17 close. The company reported positive adjusted EBITDA for the first time since Q1 2023 and 15% year-over-year revenue growth in its Life Sciences Services segment. CryoPort supports 22 approved therapies and expects further growth from new facilities and clinical trials.
Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
Conestoga Capital Advisors’ Q2 2026 investor letter highlighted Cryoport, Inc. (NASDAQ:CYRX), citing broad-based growth and management’s decision to raise full-year revenue guidance. The letter also noted CYRX’s August 6, 2026 close at $14.71, $741.42 million market cap, and 52-week gain of 94.58%.
Recent CYRX coverage spans financial news, insider activity and earnings.
BTIG maintained a Buy rating on CryoPort with a $25 price target, suggesting a 49% upside from its Sep 17 close. The company reported positive adjusted EBITDA for the first time since Q1 2023 and 15% year-over-year revenue growth in its Life Sciences Services segment. CryoPort supports 22 approved therapies and expects further growth from new facilities and clinical trials.
Earnings call provides fresh operating momentum and profitability progress, with guidance held despite macro/geopolitical uncertainty.
Guidance raise tied to clinical trial portfolio expansion and commercial pipeline could support near-term sentiment and valuation, but the article is investor-letter framing rather than a primary filing.
Results show accelerating Life Sciences Services growth and a profitability milestone, which can re-rate near-term margin expectations.
Insider selling by a senior digital/tech officer is a modest negative signal, but it is not evidence of fundamental deterioration by itself.
AlphAI scores every news story that mentions CYRX with an AI model for sentiment and relevance, and aggregates insider trades from Cryoport, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG maintained a Buy rating on CryoPort with a $25 price target, suggesting a 49% upside from its Sep 17 close. The company reported positive adjusted EBITDA for the first time since Q1 2023 and 15% year-over-year revenue growth in its Life Sciences Services segment. CryoPort supports 22 approved therapies and expects further growth from new facilities and clinical trials.
1 min readCryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted Cryoport, Inc. (NASDAQ:CYRX), citing broad-based growth and management’s decision to raise full-year revenue guidance. The letter also noted CYRX’s August 6, 2026 close at $14.71, $741.42 million market cap, and 52-week gain of 94.58%.
6 min readCryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin
4 min readZECCHINI EDWARD J (Chief Digital and Tech Officer) sold 35,000 shares of Cryoport, Inc. (CYRX) at an average of $14.50 ($14.47–$15.23, $0.51M total) across 2 trades over 2026-06-10 to 2026-06-11.
2 min readCryoport, Inc. (CYRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 tm2617057d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment (effective February 25, 2021), the Second Amendment (effective April 30, 2021), the Third Amendment (effective May 17, 2024), and the Fo
2 min readSTEFANOVICH ROBERT (Chief Financial Officer) sold 169,427 shares of Cryoport, Inc. (CYRX) at $16.27 ($2.76M total) on 2026-06-04.
2 min readMandalam Ramkumar sold 23,214 shares of Cryoport, Inc. (CYRX) at $15.44 ($0.36M total) on 2026-06-08.
1 min readCryoport Inc (CYRX) reported Q1 2026 revenue that exceeded analyst estimates, despite continued net losses, navigating a volatile market for cell and gene therapy logistics. The company specializes in temperature-controlled logistics and biostorage, positioning itself as an infrastructure partner for the advanced therapies sector. Its performance reflects strong demand in core service lines amidst growth investments and cost pressures.
4 min readInsiders at Cryoport (NASDAQ: CYRX) sold US$1.6 million worth of shares over the last year, with Chairman Jerrell Shelton making the largest individual sale. This occurred despite recent stock gains, and the selling price was even below the current market value, suggesting insiders may have viewed a lower price as reasonable. While insiders still collectively own a notable 3.6% of the company, the consistent selling without any purchases raises concerns about their confidence in the stock's future performance.
3 min read
